Experimental Prophylaxis Beneficial for Patients Undergoing HSCT
GVHD-free, relapse-free survival more common among those receiving cyclophosphamide-tacrolimus-mycophenolate mofetil prophylaxis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.